Protagonist Therapeutics (PTGX) Tops Q2 EPS by 3c

Protagonist Therapeutics (NASDAQ: PTGX) reported Q2 EPS of ($0.55), $0.03 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $5.55 million versus the consensus estimate of $7.51 million.

For earnings history and earnings-related data on Protagonist Therapeutics (PTGX) click here.

You May Also Be Interested In

• Yalla Group Limited (YALA) Reports Q2 EPS of $0.24
• Walker & Dunlop (WD) PT Lowered to $55 at Citizens Amid Interest Rate Headwinds
• Docusign (DOCU) Reiterated at Market Outperform by Citizens on Modest Improvement